Skip to main content
. 2022 Jun 23;41(1):43–53. doi: 10.1200/JCO.22.00205

FIG 3.

FIG 3.

OS in the (A) ITT population and in the (B) subset of patients with an HRRm. In the ITT population, the OS rates at 18 months were 29.9% (95% CI, 19.6 to 40.8) in the durvalumab plus olaparib group and 38.7% (95% CI, 27.5 to 49.7) in the durvalumab plus placebo group. HR, hazard ratio; HRRm, mutations in homologous recombination repair genes; HRRwt, wild-type homologous recombination repair genes; ITT, intent-to-treat; OS, overall survival; PFS, progression-free survival.